Oxford BioMedica (OXB)

Business description

Oxford BioMedica is a leader in gene and cell therapy. The lentivector technology is wide ranging, covering in vivo and ex vivo vector products. The technology underpins the proprietary clinical development pipeline in addition to third party manufacturing contracts which add validation to the platform.

Novartis extends manufacturing collaboration

Update | Pharmaceutical & healthcare | 16/10/2014

Novartis has broadened the terms of its CTL019/CART-019 manufacturing collaboration with Oxford BioMedica, with additional incentives for capacity expansion and process optimisation. The new agreement includes $14m upfront, of which $4.3m is an equity stake, with potential to receive a total of $90m over the next three years if the objectives are met. The deal clearly validates both the LentiVector platform and, equally importantly, the production skills and technical expertise being developed.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.£395.4m
Last close12.040p
High / Low (52 weeks)12.9p / 4.4p
Stock market listingLN
Forecast net debt (£m)9.4
Forecast gearing ratio (%)
SectorPharmaceutical & healthcare

Price performance

Relative *0.59.6152.2

* % Relative to local index

Company news